Q2 FY2021 Earnings
January 28, 2021
Presentation of financial information & forward-looking statements
Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated.
This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com).
In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook. Forward-looking statements can generally be identified by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology.
ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from
those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.
2 © 2021 ResMed | Q2 2021 Earnings Presentation - Jan 28, 2021
Our mission is to change 250 million lives in 2025
We're proud to offer digital and connected health solutions that help those with sleep apnea, COPD, and other respiratory diseases live happier, healthier lives in the comfort of home or care setting of their choice
During the last 12 months, we changed over 118 million lives
with our digital health products and cloud-based software solutions
ResMed at a glance
KEY STATISTICS1
LTM 2Q21 REVENUE | $3.1B |
1989 | |
FOUNDED | |
LISTED (NYSE, ASX) | 1995, RMD |
MARKET CAP | ~$30B |
HEADQUARTERS | San Diego, CA |
~7,500 | |
EMPLOYEES | |
COUNTRIES SERVED | 140+ |
SLEEP
Revenue by Business
LTM 2Q21
12%
Devices
51% | Masks & Other | |
37%
OOH SaaS
OUR BUSINESSES
RESPIRATORY CARE
Revenue by Region
LTM 2Q21
Americas | |||
12% | Sleep and | ||
Respiratory | |||
Care | |||
52% | Europe, Asia | ||
36% | and Other | ||
U.S. SaaS
SOFTWARE AS A SERVICE (SaaS)
Delivering a world-class patient experience through innovative solutions that lower overall costs for treating sleep apnea patients and improve clinical outcomes
1 As of 31DEC20
4 © 2021 ResMed | Q2 2021 Earnings Presentation - Jan 28, 2021
Changing the lives of COPD and other patients with respiratory diseases on their healthcare journey by bringing new solutions for unmet needs
- network of out-of-hospital healthcare management solutions designed to help providers deliver more personalized care, measurable results, and improved health outcomes.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
ResMed Inc. published this content on 28 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 January 2021 21:41:04 UTC.